Tuesday, August 8th, 2018, Baltimore, MD - Many areas of science and technology are experiencing rapid advances and the exponential increase in knowledge base. Aging research is no exception. Over the past 12 months substantial progress has been made in the areas of aging biomarkers, senolytics, DNA damage and DNA repair pathways, regenerative medicine and many other fields. Multiple areas of science and technology are rapidly converging and governments all over the world are recognizing the economic benefits of increasing productive longevity and reducing the health care costs via the preventative and personalized approaches.
Alex Zhavoronkov, PhD, the CEO of Insilico Medicine will present new results of the applications of deep learning on human multi modal data for the development of biologically-relevant biomarkers of aging on September 11th.
Insilico Medicine was the first company to use deep learning to integrate multiple data types from multiple sources to accurately predict the chronological age of the patient, interpret the most important features and apply transfer learning techniques to age-related diseases.
"And I am very happy to present at the 4th Annual Aging Research for Drug Discovery Forum at Basel Life. Basel is one of the world's main biopharmaceutical hubs hosting the headquarters of both Roche and Novartis. It is one of the main conferences where we usually announce our most important research results and meet new collaborators and partners. Our research uniquely bridges the latest advances in artificial intelligence with aging research. It is only logical that this forum is followed by the Artificial Intelligence and Blockchain for Healthcare forum", said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.
The 4th Annual Aging Research for Drug Discovery Forum at the EMBO/Basel Life Conference transpiring in Basel, September 11-12 is co-organized by Morten Scheibye-Knudsen, MD, PhD, the head of the biology of aging laboratory at the University of Copenhagen. The forum will feature the talks of some of the industry's most prominent scientists and entrepreneurs and expert panel discussions with active participation of the audience. It will also feature a Venture Capital panel to discuss the business models and possible directions for the nascent longevity biotechnology business.
"In the last few years it has been tremendously exciting to be part of the field of aging research. In particular, we are now seeing real progress where innovative industries are merging with basic academic scientists. This is particularly important because to drive real change in society we will need both teams playing towards the same goal. It is therefore a great pleasure to be part of the aging meeting in Basel where we have been fortunate to be able to invite some of the thought-leaders in the field both from the industry- and the academic side. I'm really looking forward to hearing about the innovative work that is ongoing towards the biggest challenges in healthcare: our aging population", said Morten Scheibye-Knudsen, MD/PhD
For the first time Jim Mellon, Gregory Bailey, MD and Alex Pickett representing Juvenescence and Juvenescence.AI, new drug discovery and development companies will make their public appearance in the context of aging and longevity.
To register for the forum, please visit: http://www.
About the Scheibye-Knudsen Laboratory
The growing proportion of the elderly population represents an increasing socioeconomic challenge, not least because of age-associated diseases. It is therefore increasingly pertinent to find interventions for age-associated diseases such as Alzheimer's, Parkinson's and cardiovascular diseases. Although the cause of aging is currently unknown accumulation of damage to our genome, the DNA, may be a contributing factor.
In the Scheibye-Knudsen lab we try to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.
Laboratory website: http://scheibye-knudsen.
About Insilico Medicine, Inc
Insilico Medicine, Inc. is an artificial intelligence company located at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D resources in Belgium, Russia, and the UK sourced through hackathons and competitions. The company utilises advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for ageing and age-related diseases. The company is pursuing internal drug discovery programs in cancer, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and ageing. Through its Pharma.AI division, Insilico provides advanced machine learning services to biotechnology, pharmaceutical, and skin care companies, foundations and national governments globally. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact.
Brief company video: https:/